Company Profile
GH Research Stock Price, News & Analysis
- Ticker:
- GHRS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland and listed in the U
Stock performance
30.64 USD (+5.18%)
Close
Last updated: August 6, 2026
1.71B USD
Market cap
Why the stock is moving
Following the latest company update, “GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update”, GHRS closed up 5.18% at $30.64 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Neuropsychiatric Therapeutics Company
GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.
GH001
GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients with differing numbers of prior treatment failures.
Delivery and Development Platform
The company is using dedicated inhalation technology and controlled clinical administration to develop short-duration treatments with potentially durable therapeutic effects.
Future catalysts
GH Research is seeking FDA alignment on a global Phase 3 pivotal program for GH001 in treatment-resistant depression.
Initiation of the global pivotal program is targeted for late 2026.
Recent news
- 01
- 02
GH Research Announces Publication of Phase 2a Postpartum Depression Results
Source: GH Research
- 03
- 04
GH Research Announces Pricing of $117.5 Million Underwritten Offering
Source: GH Research
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GH Research (GHRS)?
GH Research (GHRS) most recently closed at 30.64 USD, a +5.18% move versus the previous session.
What is the market cap of GH Research (GHRS)?
GH Research currently has a market capitalization of 1.71B USD on BioPharmSignal.
What does GH Research do?
Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients...
On which exchange is GHRS stock listed?
GH Research (GHRS) is associated with NASDAQ, Ireland and listed in the U, Biopharma.
What is Neuropsychiatric?
Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.
Which conditions is GH Research targeting with Neuropsychiatric?
Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals across patients...
How does GH Research describe recent progress with Neuropsychiatric?
GH Research is seeking FDA alignment on a global Phase 3 pivotal program for GH001 in treatment-resistant depression. Initiation of the global pivotal program is targeted for late 2026.
What is Therapeutics?
Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders.